GLP-1赛道火热,礼来竞争版图再添重要筹码!

制药网
Oct 17

10月15日,礼来公布orforglipron两项3期临床试验顶线结果,为火热的GLP-1赛道投下了一枚关键砝码。ACHIEVE-2 与 ACHIEVE-5 两项研究在第40周时,无论是有效性估计目标还是治疗方案估计目标下,orforglipron的3mg、12mg、36mg三个剂量组均顺利达成主要终点及所有关键次要终点,不仅实现了糖化血红蛋白(A1C)的大大降低,还在体重控制及多项心血管风险因子...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10